A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of PF-08046876 in Participants with Advanced Solid Tumors

The primary objective of this phase 1 study is to evaluate the safety and pharmacokinetics of PF-08046876 in participants diagnosed with advanced solid tumors. Assessing these parameters is essential for determining the maximum tolerated dose and the metabolic profile of the investigational product in a clinical setting.

The study involves a total of 240 patients. The population consists of both male and female individuals. Participants are within the age ranges corresponding to codes 3 and 4. The cohort is characterized by the presence of advanced solid tumors.

This Phase 1 study evaluates the efficacy and safety of PF-08046876 in individuals diagnosed with advanced solid tumors. The research methodology involves a sequential clinical protocol starting with a screening visit to determine eligibility. Following screening, participants proceed through scheduled follow-up visits to monitor clinical responses and safety parameters, concluding with an end-of-study visit. The total duration of participant involvement is determined by individual response to the intervention and clinical assessment. Early termination from the study may occur based on predefined clinical criteria or safety considerations.

The assessment of efficacy in this phase 1 clinical trial focuses on subjects with advanced solid tumors. No specific parameters, measurement methods, or assessment schedules were provided in the source documentation.